<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of primary adrenal insufficiency in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of primary adrenal insufficiency in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes of primary adrenal insufficiency in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mimi S Kim, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mitchell E Geffner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2380276354"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Adrenal insufficiency is a potentially life-threatening condition defined by the inability of the adrenal cortex to produce sufficient glucocorticoid and/or mineralocorticoid hormones [<a href="#rid1">1</a>]. Primary adrenal insufficiency results from disease that is intrinsic to the adrenal cortex; the most common cause in childhood is congenital adrenal hyperplasia (CAH). Central adrenal insufficiency is characterized by lack of adrenocorticotropic hormone (ACTH) stimulation of the adrenal cortex, most often as a result of prior high-dose glucocorticoid therapy (which suppresses the hypothalamic-pituitary-adrenal axis). It may also occur in the setting of a central nervous system malformation or disease and/or its treatment, eg, radiation.</p><p>The causes of primary adrenal insufficiency will be discussed in this topic review. Other aspects of adrenal insufficiency are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5815.html" rel="external">"Causes of central adrenal insufficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5825.html" rel="external">"Treatment of adrenal insufficiency in children"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW OF CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The signs and symptoms of primary adrenal insufficiency vary depending on which hormones are deficient, severity of the defect(s), and duration of the deficiency(ies)  (<a class="graphic graphic_table graphicRef66355" href="/z/d/graphic/66355.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/z/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children", section on 'Primary adrenal insufficiency'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid deficiency</strong> – Deficiency of glucocorticoids (eg, cortisol) causes fatigue, gastrointestinal complaints of nausea and vomiting, hypoglycemia in infancy and early childhood, and skin and mucosal hyperpigmentation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mineralocorticoid deficiency</strong> – Deficiency of mineralocorticoids (eg, aldosterone) causes dehydration, electrolyte abnormalities, and, potentially, hypotension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenal androgens</strong> – Adrenal androgens (eg, dehydroepiandrosterone [DHEA] or DHEAS, its sulfated derivative) are increased in congenital adrenal hyperplasia (CAH), the most common cause of primary adrenal insufficiency. Clinical manifestations may include atypical genital appearance and virilization.</p><p></p><p class="bulletIndent1">In other types of adrenal insufficiency, adrenal androgens may be deficient, with subtle manifestations that develop after puberty such as decreased sexual hair and libido.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenal crisis</strong> – Adrenal crisis results from acute adrenal insufficiency. The clinical features of adrenal crisis arise from glucocorticoid deficiency (vomiting, fever, and hypoglycemia, occasionally leading to shock) and, if present, mineralocorticoid deficiency (hyponatremia, hyperkalemia, and hypotension). Typically, both hormones are deficient and contribute to the clinical presentation. In severe cases, these deficiencies can lead to hypotension, shock, and even death. A rapid overview of this issue can be found in the accompanying table  (<a class="graphic graphic_table graphicRef61357" href="/z/d/graphic/61357.html" rel="external">table 2</a>).</p><p></p><p class="headingAnchor" id="H8"><span class="h1">PATHOGENETIC CATEGORIES OF PRIMARY ADRENAL INSUFFICIENCY</span><span class="headingEndMark"> — </span>The etiology of primary adrenal insufficiency can be classified based upon pathophysiology  (<a class="graphic graphic_table graphicRef81494" href="/z/d/graphic/81494.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Steroidogenesis disorders</strong> – Defects within the biosynthetic pathways of glucocorticoids and/or mineralocorticoids lead to impaired synthesis of cortisol and/or aldosterone. This category includes congenital adrenal hyperplasia (CAH). (See  <a class="medical medical_review" href="/z/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenal damage or dysfunction</strong> – Injury from factors extrinsic to the adrenal gland (eg, infection, drugs, autoimmunity, and hemorrhage) may impair adrenal function. Adrenal insufficiency also may develop in the setting of critical illness or mitochondrial disorders such as Kearns-Sayre syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peroxisomal disorders</strong> – The adrenal gland can be impaired by accumulation of abnormal very long-chain fatty acids within the peroxisomes (adrenoleukodystrophy [ALD] and other disorders).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic causes of adrenal hypoplasia</strong> – A lack of normal adrenocortical cell differentiation due to pathogenic genetic variants may result in adrenal hypoplasia congenita or several syndromes that include adrenal hypoplasia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inherited adrenal unresponsiveness to adrenocorticotropic hormone (ACTH)</strong> – Inherited defects in adrenal responsiveness to ACTH are seen in familial glucocorticoid deficiency (FGD) and triple A syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs</strong> – Certain drugs can cause adrenal dysfunction, including high-dose <a class="drug drug_pediatric" data-topicid="13401" href="/z/d/drug information/13401.html" rel="external">ketoconazole</a>.</p><p></p><p class="headingAnchor" id="H9"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of primary adrenal insufficiency in children is unknown. Congenital adrenal hyperplasia (CAH), which occurs in approximately 1 in 14,200 live births, is the most common cause of primary adrenal insufficiency, accounting for 70 to 85 percent of cases of primary adrenal insufficiency [<a href="#rid2">2-4</a>]. The distribution of specific causes of adrenal insufficiency varies by the populations studied.</p><p>The relative frequency of the causes of primary adrenal insufficiency in children are illustrated by two large case series from Canada and Italy [<a href="#rid2">2,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>CAH due to 21-hydroxylase deficiency – 72 to 85 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Other types of CAH – 1 to 2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune polyglandular syndrome (APS) type 1 – 3 to 5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune adrenal insufficiency (either isolated or APS type 2) – 2 to 16 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Adrenoleukodystrophy (ALD) or other peroxisomal defects – 3 to 5 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Adrenal hypoplasia congenita – 1 to 2 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Triple A syndrome – 1 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Undetermined cause – 1 to 6 percent</p><p></p><p>The rare genetic causes of primary adrenal insufficiency are illustrated by two case series that described children with primary adrenal insufficiency of initially unknown etiology (after excluding most of the most common causes, including classic CAH) [<a href="#rid5">5,6</a>]. After detailed genetic testing using a panel of candidate genes, a genetic diagnosis was reached in most of these children; the most common diagnosis was familial glucocorticoid deficiency (FGD) type 1 due to pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607397&amp;token=87jLzclRwWxNoI%2BQq5Gg7522brIHwqZKuIwjrcaWuRe6jUGvt5iGY%2FJkruq%2BWDg7&amp;TOPIC_ID=5813" target="_blank"><i>MC2R</i></a> gene (20 to 30 percent of the unexplained adrenal insufficiency in this cohort). The remainder had other forms of FGD, triple A syndrome, uncommon forms of CAH, or various forms of adrenal hypoplasia congenita.</p><p class="headingAnchor" id="H10"><span class="h1">DISORDERS OF STEROIDOGENESIS</span><span class="headingEndMark"> — </span>Pathogenic variants of the genes encoding enzymes in the biosynthetic pathways of the adrenocortical hormones result in the decreased production of glucocorticoids and/or mineralocorticoids. Steroidogenic disorders of cortisol (congenital adrenal hyperplasia [CAH]) are major causes of primary adrenal insufficiency in children [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Congenital adrenal hyperplasia</span><span class="headingEndMark"> — </span>Inherited defects in the enzymatic steps of cortisol biosynthesis (steroidogenesis) result in disease states termed congenital adrenal hyperplasia (CAH)  (<a class="graphic graphic_figure graphicRef79609" href="/z/d/graphic/79609.html" rel="external">figure 1</a>). These disorders cause primary adrenal insufficiency because they impair cortisol synthesis  (<a class="graphic graphic_table graphicRef76865" href="/z/d/graphic/76865.html" rel="external">table 4</a>).</p><p>The resulting decrease in cortisol levels increases the secretion of adrenocorticotropic hormone (ACTH), thereby stimulating the production of adrenal steroids up to and including the substrate for the defective enzyme. This chronic ACTH stimulation results in hyperplasia of the adrenal cortex. (See  <a class="medical medical_review" href="/z/d/html/120.html" rel="external">"Adrenal steroid biosynthesis"</a>.)</p><p>The clinical manifestations of these disorders are related to one or more of the following pathologic processes:</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoid deficiency – Impaired synthesis of cortisol.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mineralocorticoid deficiency – Impaired synthesis of aldosterone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excessive androgens (or other adrenal hormones) – Lack of negative feedback causes increased pituitary ACTH secretion, which leads, in turn, to excessive synthesis of precursor steroids and oversecretion of steroids whose production does not require the deficient enzyme. These are most commonly androgenic hormones, which cause virilization.</p><p></p><p class="bulletIndent1">In some types of CAH (eg, 11-beta-hydroxylase deficiency), there is excessive synthesis of mineralocorticoids such as deoxycorticosterone, which can cause hypertension.</p><p></p><p>The following is a brief summary of the various forms of CAH based upon their enzymatic defects  (<a class="graphic graphic_figure graphicRef79609" href="/z/d/graphic/79609.html" rel="external">figure 1</a>), each of which is discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>21-hydroxylase deficiency</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F201910&amp;token=tEpDslnpc0F0kICl%2Fz7sFRq9f0MGN2Oxgakbp76u2bH6r5apeNBE4pQAJecy75mT&amp;TOPIC_ID=5813" target="_blank">MIM #201910</a>) – 21-hydroxylase deficiency (due to pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610613&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7nKcANu%2FKoJjf%2BXbeNO%2FG5&amp;TOPIC_ID=5813" target="_blank"><i>CYP21A2</i></a> gene) accounts for 70 to 85 percent of percent of cases of primary adrenal insufficiency. It is one of the most common (autosomal recessively) inherited diseases. The more severe or "classic" form occurs in approximately 1 in 15,000 live births  (<a class="graphic graphic_figure graphicRef79609" href="/z/d/graphic/79609.html" rel="external">figure 1</a>). It usually presents as one of two clinical syndromes in neonates or very young infants:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A salt-wasting form (hyponatremia, hyperkalemia, and hypotension on account of associated mineralocorticoid deficiency), with atypical genital appearance in affected females (because of adrenal androgen excess)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A simple virilizing form in affected males and females without salt wasting</p><p></p><p class="bulletIndent1">(See  <a class="medical medical_review" href="/z/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>11-beta-hydroxylase deficiency</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F202010&amp;token=tEpDslnpc0F0kICl%2Fz7sFRq9f0MGN2Oxgakbp76u2bHmIkDTAKpODFbzXY9foHOw&amp;TOPIC_ID=5813" target="_blank">MIM #202010</a>) – 11-beta-hydroxylase deficiency (due to pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610613&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7nKcANu%2FKoJjf%2BXbeNO%2FG5&amp;TOPIC_ID=5813" target="_blank"><i>CYP11B1</i></a> gene) accounts for less than 5 percent of CAH cases  (<a class="graphic graphic_figure graphicRef79609" href="/z/d/graphic/79609.html" rel="external">figure 1</a>). Cortisol synthesis is reduced, as in other forms of CAH; however, in this form, there is excessive mineralocorticoid (deoxycorticosterone) accompanying adrenal androgen overproduction. This causes increased sodium retention and hypertension; affected females also have virilization. (See  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on '11-beta-hydroxylase deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>3-beta-hydroxysteroid dehydrogenase type 2 deficiency</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F201810&amp;token=tEpDslnpc0F0kICl%2Fz7sFRq9f0MGN2Oxgakbp76u2bHj%2FVtZgxDtClXmtQmC0U12&amp;TOPIC_ID=5813" target="_blank">MIM #201810</a>) – 3-beta-hydroxysteroid dehydrogenase type 2 (due to pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613890&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5oKjeJqC3WAvESkV%2BKrJFz&amp;TOPIC_ID=5813" target="_blank"><i>HSD3B2</i></a> gene) is a rare form of CAH characterized by impaired synthesis of all steroid hormones, resulting in deficiencies of glucocorticoids, mineralocorticoids, and active androgens  (<a class="graphic graphic_figure graphicRef79609" href="/z/d/graphic/79609.html" rel="external">figure 1</a>). Most patients present as neonates or in early infancy. Clinical manifestations result from both cortisol and aldosterone deficiency, including feeding difficulties, vomiting, volume depletion, hyponatremia, and hyperkalemia. Affected females may have mild virilization (an indirect effect of oversecretion of dehydroepiandrosterone [DHEA]), and males have varying degrees of failure of normal genital development, ranging from hypospadias to more severe ambiguity of the external genitalia. (See  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on '3-beta-hydroxysteroid dehydrogenase type 2 deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>17-alpha-hydroxylase deficiency</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F202110&amp;token=tEpDslnpc0F0kICl%2Fz7sFRq9f0MGN2Oxgakbp76u2bHke1yVQbhhAZ9cGmB9hLhT&amp;TOPIC_ID=5813" target="_blank">MIM #202110</a>) – 17-alpha-hydroxylase deficiency (due to pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609300&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaEon7sjNFcNdYyLkr8BB8jV&amp;TOPIC_ID=5813" target="_blank"><i>CYP17A1</i></a> gene) is a rare form of CAH. Patients usually have both 17-alpha-hydroxylase and 17,20-lyase deficiencies  (<a class="graphic graphic_figure graphicRef79609" href="/z/d/graphic/79609.html" rel="external">figure 1</a>). Although sufficient cortisol is not produced, large quantities of corticosterone (a steroid with both glucocorticoid and mineralocorticoid activities) are synthesized, reducing the symptoms associated with cortisol deficiency. There is also excess production of deoxycorticosterone, resulting in hypertension. In addition, given that both androgen and estrogen synthesis are impaired, affected male patients have female external genitalia and a blind vagina and affected females have primary amenorrhea and absent secondary sexual characteristics. (See  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'CYP17A1 deficiencies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital lipoid adrenal hyperplasia</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F201710&amp;token=tEpDslnpc0F0kICl%2Fz7sFRq9f0MGN2Oxgakbp76u2bFvCBDA0t4oT9zSTHwPlUgJ&amp;TOPIC_ID=5813" target="_blank">MIM #201710</a>) – Congenital lipoid adrenal hyperplasia is the rarest and usually the most severe form of CAH. Pathogenic variants in the steroidogenic acute regulatory protein (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600617&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyp%2BpEbg8KqXutOGZPB5lVMt&amp;TOPIC_ID=5813" target="_blank"><i>StAR</i></a>) gene result in an inability to convert cholesterol to pregnenolone, thereby precluding the biosynthesis of all of the major adrenal steroids. The adrenal glands are filled with lipid granules. Patients present as neonates or young infants with symptoms and signs of adrenocortical insufficiency, including poor feeding, vomiting, lethargy, volume depletion, respiratory distress, hyponatremia, hyperkalemia, hypoglycemia, and metabolic acidosis. Affected male infants usually have female external genitalia because of the lack of testicular androgen production, and affected female infants have normally developed genitalia. (See  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Lipoid congenital adrenal hyperplasia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>P450 side-chain cleavage (P450SCC) deficiency</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613743&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4r88rizq%2B6xNrLhjZCyKTZ&amp;TOPIC_ID=5813" target="_blank">MIM #613743</a>) – Pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F118485&amp;token=tEpDslnpc0F0kICl%2Fz7sFcemwJDECTAEOjrtgoDyO4K4T2ZzRpsVZOq5Tz28TKPN&amp;TOPIC_ID=5813" target="_blank"><i>CYP11A1</i></a> gene can lead to a phenotype similar to that of congenital lipoid adrenal hyperplasia, with a more variable age of onset of adrenal insufficiency and a spectrum of external genitalia ranging from complete female to normal male. In addition, <em>CYP11A1</em> gene pathogenic variants have been identified in milder forms of adrenal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'Cholesterol side-chain cleavage enzyme (CYP11A1) deficiency'</a> and  <a class="medical medical_review" href="/z/d/html/118045.html" rel="external">"Causes of differences of sex development", section on 'Other types of congenital adrenal hyperplasia'</a> and <a class="local">'Familial glucocorticoid deficiency'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>P450 oxidoreductase (POR) deficiency</strong> (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613571&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz74yOXGMcuI5lr9jc5HZCj9&amp;TOPIC_ID=5813" target="_blank">MIM #613571</a>) – POR deficiency, a rare variant, is caused by a pathogenic variant in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F124015&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1Q4a5%2BaVouwpT3l8wwEjDbH&amp;TOPIC_ID=5813" target="_blank"><i>POR</i></a> gene that encodes cytochrome POR, an enzyme that transfers electrons to CYP21A2 and CYP17A1. This causes a partial deficiency of the enzymes 21-hydroxylase and 17-alpha-hydroxylase, respectively. The condition also known as apparent combined CYP21A2 and CYP17A1 deficiencies, although pathogenic variants in the <em>CYP21A2</em> and <em>CYP17</em> genes have not been identified in affected individuals. Affected girls are born with atypical genital appearance, suggesting intrauterine androgen excess; however, in contrast with classic CAH, postnatal serum androgen concentrations are low and virilization does not progress. Boys may have undervirilization. Mothers may have virilization during pregnancy with an affected fetus. Some children also have bone malformations primarily affecting the head and limbs, known as Antley-Bixler syndrome [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/15686.html" rel="external">"Uncommon congenital adrenal hyperplasias", section on 'P450 oxidoreductase deficiency (apparent combined CYP17A1 and CYP21A2 deficiency)'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Defects in aldosterone production</span><span class="headingEndMark"> — </span>Pathogenic variants of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F124080&amp;token=tEpDslnpc0F0kICl%2Fz7sFdXuSx8tgoT0Op78emVEd1SyE9eXgFxGcMCDsA4%2B9kxy&amp;TOPIC_ID=5813" target="_blank"><i>CYP11B2</i></a> gene are the major genetic causes of impaired mineralocorticoid synthesis  (<a class="graphic graphic_figure graphicRef79609" href="/z/d/graphic/79609.html" rel="external">figure 1</a>). As there is no concomitant defect in cortisol biosynthesis, ACTH is not stimulated and, hence, there is no hyperplasia of the adrenal glands as is seen in CAH. Patients usually present in infancy with symptoms of aldosterone deficiency. These include dehydration, salt wasting with hyponatremia and hyperkalemia, and failure to thrive.</p><p>The<em> CYP11B2</em> gene encodes aldosterone synthase, the terminal enzyme in the aldosterone biosynthetic pathway. Pathogenic variants in this gene impair the production of aldosterone either by interfering with the 11-hydroxylation of 11-deoxycorticosterone (usually referred to as DOC) to form corticosterone and 18-hydroxycorticosterone (aldosterone synthase deficiency type 1, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F203400&amp;token=tEpDslnpc0F0kICl%2Fz7sFRq9f0MGN2Oxgakbp76u2bEi%2F%2FvE53qh4DRvoWVqwG08&amp;TOPIC_ID=5813" target="_blank">MIM #203400</a>) or by interfering with the 18-oxidation of 18-hydroxycorticosterone to form aldosterone (aldosterone synthase deficiency type 2, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610600&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4p%2BOr5K4LJ4uqvomHtmWGd&amp;TOPIC_ID=5813" target="_blank">MIM #610600</a>) [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)", section on 'Congenital isolated hypoaldosteronism'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Defects in cholesterol biochemistry</span><span class="headingEndMark"> — </span>Conditions that alter cholesterol availability for steroidogenesis also may present as primary adrenal insufficiency. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lysosomal acid lipase deficiency</strong> – Lysosomal acid lipase deficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F278000&amp;token=87jLzclRwWxNoI%2BQq5Gg74ZQlR%2BcogWr9WYcwQp%2F1Tz0wrkNoJJ4UIC8XdQTwhfc&amp;TOPIC_ID=5813" target="_blank">MIM #278000</a>, or cholesterol ester hydrolase deficiency) occurs because of an autosomal recessive defect in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F613497&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5ByVLtmKXMMM03gvGE6OjM&amp;TOPIC_ID=5813" target="_blank"><i>LIPA</i></a> gene [<a href="#rid9">9</a>]. Lysosomal acid lipase catalyzes the hydrolysis of cholesterol esters and triglycerides, and its deficiency results in abnormal serum lipid profile in almost all patients [<a href="#rid10">10,11</a>]. Patients develop massive accumulation of lysosomal esterified lipids in target organs.</p><p></p><p class="bulletIndent1">This disorder has two forms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Wolman disease</strong> – This is a fulminant form that presents in infants. It is characterized by calcifications in the adrenal glands and primary adrenal insufficiency. Other features include hepatosplenomegaly, hepatic fibrosis, malabsorption, vomiting, and poor weight gain, all of which contribute to early death by one year of age [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cholesterol ester storage disease</strong> – This is a milder phenotype that presents later in life and is characterized by hepatic disease, without adrenal insufficiency (although adrenal calcifications may be present) [<a href="#rid11">11,14</a>]. Key clinical characteristics at presentation include moderate liver enzyme elevations, dyslipidemia (elevated low-density lipoprotein and low high-density lipoprotein), and hepatomegaly with hepatic steatosis and variable degrees of fibrosis [<a href="#rid15">15</a>]. The disorder is often misdiagnosed as nonalcoholic fatty liver disease or a lipid storage disease (eg, Gaucher or Niemann-Pick disease). (See  <a class="medical medical_review" href="/z/d/html/115661.html" rel="external">"Metabolic dysfunction-associated steatotic liver disease in children and adolescents", section on 'Tests to exclude other liver diseases'</a> and  <a class="medical medical_review" href="/z/d/html/89223.html" rel="external">"Overview of the evaluation of hepatomegaly in adults", section on 'Storage disorders'</a>.)</p><p></p><p class="bulletIndent1">The disorder can be diagnosed with molecular testing and/or by using an enzyme-based biochemical test, which is commercially available [<a href="#rid16">16</a>]. A list of laboratories that perform this test is available at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=5813" target="_blank">Genetic Testing Registry website</a>.</p><p></p><p class="bulletIndent1">Successful treatment of lysosomal acid lipase deficiency in infants and adults has been reported with <a class="drug drug_pediatric" data-topicid="108897" href="/z/d/drug information/108897.html" rel="external">sebelipase alfa</a>, a recombinant human lysosomal acid lipase that replaces the deficient enzyme [<a href="#rid17">17-21</a>]. The drug is approved for use in the United States and several other countries [<a href="#rid22">22</a>]. Prior studies reported successful treatment with bone marrow transplantation [<a href="#rid23">23</a>] and stem cells derived from umbilical cord blood [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smith-Lemli-Opitz syndrome</strong> – Smith-Lemli-Opitz syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F270400&amp;token=87jLzclRwWxNoI%2BQq5Gg73Meq6pGT2ugvxa5STKpyCVPDlCy%2FGVvJqatHDgpjwln&amp;TOPIC_ID=5813" target="_blank">MIM #270400</a>) is an autosomal recessive disorder of cholesterol biosynthesis caused by pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F602858&amp;token=87jLzclRwWxNoI%2BQq5Gg7xhuIbwocJg2ipzTTi45kuMneMMeTz6UtCsHNXP9DYM8&amp;TOPIC_ID=5813" target="_blank"><i>DHCR7</i></a> gene [<a href="#rid25">25</a>]. The enzyme encoded by this gene is required to convert 7-dehydrocholesterol to cholesterol. The syndrome includes microcephaly, micrognathia, low-set posteriorly rotated ears, and syndactyly of the second and third toes. Affected males have either ambiguous genitalia or nearly normal-appearing female external genitalia  (<a class="graphic graphic_picture graphicRef55839" href="/z/d/graphic/55839.html" rel="external">picture 1</a>). Adrenal insufficiency is not universal, but a number of patients have presented with mineralocorticoid deficiency [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h1">ADRENAL DAMAGE OR DYSFUNCTION</span><span class="headingEndMark"> — </span>Bilateral destruction of the adrenal glands by factors extrinsic to the adrenal gland causes adrenal insufficiency in a significant number of children, although this is a less common mechanism of adrenal insufficiency than in adults.</p><p class="headingAnchor" id="H15"><span class="h2">Adrenal hemorrhagic infarction</span><span class="headingEndMark"> — </span>Causes of adrenal hemorrhagic infarction include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular injury</strong> – In newborn infants, birth injury to the subcapsular vascular plexus can cause bilateral subcapsular bleeding into the adrenal glands and ischemic damage [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial infection</strong> – Children with serious bacterial infection occasionally develop bilateral adrenal hemorrhage or infarction because of bacterial endotoxin, leading to life-threatening adrenal crisis. This is classically caused by <em>Neisseria</em> <em>meningitidis</em> and is known as Waterhouse-Friderichsen syndrome. It has also been reported with <em>Haemophilus influenzae </em>type B, <em>Pseudomonas aeruginosa</em>, <em>Streptococcus pneumoniae</em>, group B <em>streptococcus</em>, and <em>Staphylococcus aureus</em>. (See  <a class="medical medical_review" href="/z/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a> and  <a class="medical medical_review" href="/z/d/html/2135.html" rel="external">"Clinical manifestations of Staphylococcus aureus infection in adults", section on 'Other manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulant therapy</strong> – Anticoagulant therapy and hypercoagulable states are important risk factors for adrenal hemorrhage. (See  <a class="medical medical_review" href="/z/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Hemorrhagic infarction'</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Autoimmune disease</span><span class="headingEndMark"> — </span>Cell-mediated immune mechanisms may cause adrenal damage, resulting in primary adrenal insufficiency, typically called Addison disease. Autoimmune injury causes 15 percent of cases of primary adrenal insufficiency in children [<a href="#rid2">2</a>], although this mechanism is a major cause of primary disease in adults. (See  <a class="medical medical_review" href="/z/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Autoimmune adrenalitis'</a>.)</p><p>Approximately one-half of patients with autoimmune adrenal insufficiency also have autoimmune destruction of other endocrine glands. This combination, known as autoimmune polyglandular syndrome (APS), is observed more frequently in females. Two syndromes, named APS1 and APS2, have specific combinations of autoimmune adrenal insufficiency and involvement of other endocrine organs.</p><p class="bulletIndent1"><span class="glyph">●</span>APS1 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F240300&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FfWzCTGwFXhORtgmdRwWxSPRob3gbdKo6N1THWxtH2a&amp;TOPIC_ID=5813" target="_blank">MIM #240300</a>), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), includes hypoparathyroidism, chronic mucocutaneous candidiasis, and adrenal insufficiency. Other findings include primary hypogonadism and malabsorption. This disease is due to pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607358&amp;token=87jLzclRwWxNoI%2BQq5Gg793jF9b%2BCrGsi9EkN1%2FuJD2WPCgjmhGbUdAz8dugSN5Y&amp;TOPIC_ID=5813" target="_blank"><i>AIRE</i></a> (autoimmune regulator) gene [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>APS2 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F269200&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2BRVL8I86dIflO0G3sA3ml5iRqfPqqIikadEKTGPmKOv&amp;TOPIC_ID=5813" target="_blank">MIM %269200</a>), also known as Schmidt syndrome, is primarily characterized by primary adrenal insufficiency; thyroiditis and type 1 diabetes mellitus are associated findings in some patients. APS2 is more prevalent than APS1. The age of onset ranges from childhood to late adulthood, with most cases presenting between 20 to 40 years of age.</p><p></p><p>The polyglandular autoimmune syndromes are discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Polyglandular autoimmune syndromes'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Infection of the adrenal gland with the following organisms can lead to adrenal insufficiency in children:</p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis – In miliary tuberculosis, <em>Mycobacterium tuberculosis</em> can infiltrate and destroy the adrenal glands. Adrenal calcifications are sometimes seen on abdominal radiographs. (See  <a class="medical medical_review" href="/z/d/html/8024.html" rel="external">"Clinical manifestations, diagnosis, and treatment of miliary tuberculosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fungal infections – Adrenal insufficiency may develop in disseminated histoplasmosis and, less often, in coccidioidomycosis and blastomycosis. (See  <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis", section on 'Adrenal involvement'</a> and  <a class="medical medical_review" href="/z/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Disseminated fungal infections'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection – HIV disease is associated with a variety of abnormalities in pituitary and adrenal function, but overt adrenal insufficiency is rare. In addition, adrenocortical function can be altered by medications used in the treatment of HIV infection, including <a class="drug drug_pediatric" data-topicid="13401" href="/z/d/drug information/13401.html" rel="external">ketoconazole</a>, <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">rifampin</a>, and <a class="drug drug_pediatric" data-topicid="12578" href="/z/d/drug information/12578.html" rel="external">megestrol acetate</a>. (See  <a class="medical medical_review" href="/z/d/html/3720.html" rel="external">"Pituitary and adrenal gland dysfunction in patients with HIV"</a>.)</p><p></p><p>Infectious adrenalitis is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Infectious adrenalitis'</a>.)</p><p class="headingAnchor" id="H2404714976"><span class="h2">Mitochondrial disorders</span><span class="headingEndMark"> — </span>Case reports describe adrenal insufficiency developing in some individuals with mitochondrial disorders related to pathogenic variants in mitochondrial DNA. The disorders include Kearns-Sayre syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F530000&amp;token=87jLzclRwWxNoI%2BQq5Gg73PUDOXR9a51bb21LFj9QviHSq5qgJlvKHciI%2B6iLEG5&amp;TOPIC_ID=5813" target="_blank">MIM #530000</a>), a mitochondrial DNA deletion syndrome (chronic progressive external ophthalmoplegia with onset during childhood, heart block, and retinal pigmentary changes) [<a href="#rid29">29,30</a>], and Pearson syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F557000&amp;token=87jLzclRwWxNoI%2BQq5Gg76nClTFje4YId1FBT3WcPShFzW5Jifys5hqKU2yoE5mi&amp;TOPIC_ID=5813" target="_blank">MIM #557000</a>; sideroblastic anemia and pancreatic dysfunction) [<a href="#rid31">31</a>]. MELAS syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F540000&amp;token=87jLzclRwWxNoI%2BQq5Gg78rdzGng57%2BUERMWba9lkxl3s4Jqy2oG45DVDUnaQO99&amp;TOPIC_ID=5813" target="_blank">MIM #540000</a>; mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) has also been associated with adrenal insufficiency. An autosomal dominant mitochondrial disorder due to <em>POLG1</em> (polymerase, DNA, gamma-1) gene pathogenic variants can cause adrenal insufficiency as well [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/6271.html" rel="external">"Myopathies affecting the extraocular muscles in children", section on 'Kearns-Sayre syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/7122.html" rel="external">"Causes and pathophysiology of the sideroblastic anemias", section on 'Pearson syndrome (large deletion of mitochondrial DNA)'</a>.)</p><p class="headingAnchor" id="H2712108"><span class="h2">Critical illness-related corticosteroid insufficiency</span><span class="headingEndMark"> — </span>Critical illness-related corticosteroid insufficiency (CIRCI) is defined as dysfunction of the hypothalamic-pituitary-adrenal axis that occurs during critical illness [<a href="#rid32">32</a>]. The most common clinical manifestation is pressor-resistant hypotension. This was first described in adults with sepsis and has subsequently been reported in children [<a href="#rid33">33,34</a>]. It is thought to be caused by adrenal insufficiency together with tissue corticosteroid resistance. It is characterized by an exaggerated and protracted proinflammatory response, especially in the settings of septic shock and in early severe acute respiratory distress syndrome. (See  <a class="medical medical_review" href="/z/d/html/1654.html" rel="external">"Glucocorticoid therapy in septic shock in adults"</a>.)</p><p>Affected patients have decreased basal cortisol production and synthesis, presumed to be due to adrenal damage causing loss of adrenal reserve or substrates for steroidogenesis. They also have an inadequate cortisol response to stress and/or to an intravenous cosyntropin (ACTH) stimulation test. Of note, a low total cortisol concentration in a critically ill patient may be caused by hypoproteinemia (more specifically, low corticosteroid-binding globulin, also known as transcortin and serpin A6), even when adrenal function and free cortisol are normal [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults", section on 'Critical illness'</a>.)</p><p class="headingAnchor" id="H2712189"><span class="h2">Transient adrenal insufficiency in premature infants</span><span class="headingEndMark"> — </span>Premature infants have multiple risk factors for relative adrenal insufficiency. The adrenal cortex has not yet undergone the normal physiologic switch from the fetal adrenal cortex, which is focused on the production of sex steroid precursors, to the mature function of the adult adrenal cortex, which is focused on the production of cortisol and aldosterone, as well as androgen precursors. In addition, critical illness adds stress that may further impair cortisol production [<a href="#rid36">36</a>]. The immaturity of the adrenocortical response to stress is reflected in a high ratio of cortisol precursors to cortisol in these infants [<a href="#rid37">37</a>]. As in older patients, refractory hypotension is a clinical manifestation that responds to <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> treatment. There are conflicting data in the literature regarding the clinical significance of transient adrenal insufficiency in prematurity, and standards regarding its diagnosis are lacking.</p><p class="headingAnchor" id="H18"><span class="h1">PEROXISOMAL DISORDERS</span><span class="headingEndMark"> — </span>Peroxisomes are subcellular organelles that are present in all cells except mature erythrocytes. These structures catalyze numerous catabolic functions (eg, beta-oxidation of very long-chain fatty acids) and anabolic functions (eg, bile acid synthesis). (See  <a class="medical medical_review" href="/z/d/html/6147.html" rel="external">"Peroxisomal disorders"</a>.)</p><p>Peroxisomal disorders are a heterogeneous group of inborn errors of metabolism. They may either result from a defect in a single peroxisomal enzyme or from abnormal peroxisomal biogenesis affecting multiple peroxisomal functions.</p><p>The clinical manifestations of peroxisomal disorders vary. Neurologic impairment is observed in most peroxisomal disorders. The adrenal gland is involved in adrenoleukodystrophy (ALD), as well as in the disorders resulting from abnormal peroxisome biogenesis (such as neonatal ALD, Refsum disease, and Zellweger syndrome).</p><p class="headingAnchor" id="H19"><span class="h2">Adrenoleukodystrophy</span><span class="headingEndMark"> — </span>ALD consists of a spectrum of phenotypes that vary in age and severity of clinical presentation. It is an X-linked disorder and thus causes clinical disease primarily in males, which affects adrenal function, testicular function, and central and peripheral nervous systems. Female heterozygotes occasionally develop symptoms in adulthood. In boys with a new presentation of primary adrenal insufficiency, prompt evaluation for ALD is important because early diagnosis of ALD is likely to improve outcomes. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy"</a>.)</p><p>Several clinical phenotypes have been described in boys and men with X-linked ALD, including childhood cerebral ALD, adolescent cerebral ALD, adult cerebral ALD, adrenomyeloneuropathy, and adrenal insufficiency alone  (<a class="graphic graphic_table graphicRef70311" href="/z/d/graphic/70311.html" rel="external">table 5</a>). The form with adrenal insufficiency alone usually presents between two and eight years of age. Different phenotypes also can be seen in a single pedigree. Adrenal failure may predate, occur simultaneously with, or follow the onset of the neurologic deterioration. Adrenal insufficiency is the initial manifestation in 38 percent of patients with ALD and eventually develops in more than 80 percent of patients over their lifetime [<a href="#rid38">38,39</a>].</p><p>Newborn screening for ALD has been implemented in most of the United States. Information on implementation by individual states and other countries around the world (eg, Taiwan, Japan, the Netherlands) is available on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fadrenoleukodystrophy.info%2Fclinical-diagnosis%2Fald-newborn-screening&amp;token=%2BxsTaOwWn3BQE2sXVnLf1HNOZlDdmfBC4CO2xNRTL6p4i38kWDRX%2B8in1QytWtzPj2OfRJnXb%2FN6jTfZbvRvWtAkn2QeaujYip%2BhdSdh%2FXc%3D&amp;TOPIC_ID=5813" target="_blank">ALD database website</a>. Newborn screening allows for early identification of the condition prior to the development of adrenal insufficiency, as well as the timely identification of boys with cerebral ALD to permit appropriate monitoring and treatment with hematopoietic cell transplantation [<a href="#rid38">38</a>]. Individuals who are diagnosed with ALD with newborn screening require surveillance to monitor for disease manifestations including adrenal insufficiency [<a href="#rid40">40</a>]. The early identification of impairment in adrenal reserve and timely initiation of glucocorticoid replacement treatment could prevent morbidity associated with adrenal insufficiency in these patients [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Evaluation and diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/141588.html" rel="external">"Management and prognosis of X-linked adrenoleukodystrophy", section on 'Surveillance'</a>.)</p><p>ALD is caused by pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F300371&amp;token=87jLzclRwWxNoI%2BQq5Gg7ybF%2F2sVxraf85qZ3Fv%2Bpvo%2Fqjdk3y2%2B7mpIgvYErKRA&amp;TOPIC_ID=5813" target="_blank"><i>ABCD1</i></a> gene, which prevent normal transport of very long-chain fatty acids into peroxisomes, thereby preventing beta-oxidation and breakdown of very long-chain fatty acids. Accumulation of abnormal very long-chain fatty acids in affected organs (central nervous system, Leydig cells of the testes, and adrenal cortex) is presumed to be the underlying pathologic process of these disorders [<a href="#rid42">42</a>]. In the adrenal gland, abnormal very long-chain fatty acids may directly alter cellular function by inhibiting the effects of adrenocorticotropic hormone (ACTH) on the adrenocortical cells or indirectly by initiating an autoimmune response. In almost all cases, adrenocortical failure occurs, along with irreversible degenerative neurologic defects. (See  <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">"Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy"</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Other causes</span><span class="headingEndMark"> — </span>In Zellweger syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F214100&amp;token=87jLzclRwWxNoI%2BQq5Gg7yzFYVk50VYREZsptABJmrNne%2FCxLZfKcQzYjxJXH1pV&amp;TOPIC_ID=5813" target="_blank">MIM #214100</a>) and its variants, the neurologic and adrenocortical abnormalities present in the neonatal period [<a href="#rid43">43,44</a>]. With these autosomal recessive disorders, pathogenic variants have been identified in the genes encoding for peroxins (primarily <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F602136&amp;token=87jLzclRwWxNoI%2BQq5Gg79Hp59whEdpDPWWB4TolZaLvlkQ8AT%2F6V4%2B588%2FOrwhm&amp;TOPIC_ID=5813" target="_blank"><i>PEX1</i></a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F601498&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2B0RxTvmWbdYvhe5PNyrA%2BPvZwLX2OdmpOH8HN4T3sZ%2F&amp;TOPIC_ID=5813" target="_blank"><i>PEX6</i></a>), which are required for peroxisomal biogenesis. (See  <a class="medical medical_review" href="/z/d/html/6147.html" rel="external">"Peroxisomal disorders", section on 'Zellweger spectrum disorders'</a>.)</p><p>All of these pathogenic variants result in cellular accumulation of abnormal very long-chain fatty acids, as seen in ALD. However, unlike in ALD, the peroxisomes in these diseases are fewer in number and smaller than normal in size. In Zellweger syndrome, peroxisomes are totally absent and affected infants generally do not survive their first year of life.</p><p class="headingAnchor" id="H21"><span class="h1">GENETIC CAUSES OF ADRENAL HYPOPLASIA</span></p><p class="headingAnchor" id="H22"><span class="h2">Adrenal hypoplasia congenita</span><span class="headingEndMark"> — </span>Adrenal hypoplasia congenita is usually an X-linked disorder caused by pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F300473&amp;token=tEpDslnpc0F0kICl%2Fz7sFfZgq3tROP1vh4DhckKBw6Hmkf%2Fhbd68yR6dn5qfYhKu&amp;TOPIC_ID=5813" target="_blank"><i>NR0B1</i> (<i>DAX1</i>) </a>gene (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F300200&amp;token=87jLzclRwWxNoI%2BQq5Gg7yuHuYkXmKxM6FmDAzIw%2BxBjszVsovuCL2iniWJFd9fw&amp;TOPIC_ID=5813" target="_blank">MIM #300200</a>). <em>NR0B1</em> is expressed in the adrenal cortex, gonads, hypothalamus, and pituitary gland. Male fetuses with pathogenic variants have abnormal development of the adrenal cortex during the first trimester of gestation, resulting in impaired cortisol and aldosterone secretion. In a series of 155 pediatric patients with unexplained primary adrenal insufficiency (after excluding congenital adrenal hyperplasia [CAH] and other common causes), 8 percent had pathogenic variants in <em>NR0B1</em>/<em>DAX1 </em>[<a href="#rid5">5</a>].</p><p>Pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F184757&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfjmmX14QGylCDpT81AUMS1KnQFQU6eBe3%2BL9BSaRyl&amp;TOPIC_ID=5813" target="_blank"><i>NR5A1</i></a> (<em>SF1</em>) gene can also cause adrenal hypoplasia (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F612964&amp;token=87jLzclRwWxNoI%2BQq5Gg7xYxpSV2%2Fnu1qbdGXKlYNxEw2nT%2Fz6T%2FwM5L952v4ly%2F&amp;TOPIC_ID=5813" target="_blank">MIM #612964</a>), as well as a spectrum of differences in sex development [<a href="#rid5">5,45</a>]. The <em>NR5A1</em> gene regulates tissue-specific expression of cytochrome P450 steroid hydroxylases and is expressed in the gonads, adrenal glands, anterior pituitary gland, and hypothalamus. It interacts with <em>NR0B1</em>/<em>DAX1</em> and is important in both male sexual differentiation and adrenal gland development. (See  <a class="medical medical_review" href="/z/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)"</a>.)</p><p>Although most patients with adrenal hypoplasia congenita present as neonates (one to four weeks of age), the age and severity of the disease can vary. Some individuals, for example, present later in childhood. Clinical manifestations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal presentation – Affected neonates most often present with signs and symptoms of a salt-losing crisis similar to that of classic CAH, including hyponatremia, hyperkalemia, hypovolemia, and hypotension. Patients have low serum cortisol and aldosterone levels and elevated plasma adrenocorticotropic hormone (ACTH) levels, as well as hyperpigmentation. (See  <a class="medical medical_review" href="/z/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children", section on 'Adrenal crisis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypogonadotropic hypogonadism – In surviving affected males treated with replacement steroids, prepubertal gonadal development is normal, but pubertal development is impaired, resulting in hypogonadism. The site of the defect appears to be within the hypothalamic-pituitary-gonadal axis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atypical genital appearance – Infants with <em>NR5A1</em> gene pathogenic variants may present with 46,XY sex reversal, with atypical genital appearance noted at birth in affected males (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F612965&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FybkOIV%2FjOQjWHJBzV4pc4%2FREIMvi%2BqjQmHH%2FgqXcKA&amp;TOPIC_ID=5813" target="_blank">MIM #612965</a>), with or without adrenal insufficiency [<a href="#rid45">45,46</a>].</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Syndromes with adrenal hypoplasia</span><span class="headingEndMark"> — </span>Case studies of patients with adrenal hypoplasia who do not have a <em>NR0B1</em>/<em>DAX1</em> gene pathogenic variants have been reported. The underlying defects in these patients include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MIRAGE syndrome</strong> – MIRAGE syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617053&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4AN0SnNVhCo3ZYm12LspjF&amp;TOPIC_ID=5813" target="_blank">MIM #617053</a>) is characterized by <strong>m</strong>yelodysplasia, <strong>i</strong>nfection, <strong>r</strong>estriction of growth, <strong>a</strong>drenal hypoplasia, <strong>g</strong>enital phenotypes, and <strong>e</strong>nteropathy. It is caused by heterozygous pathogenic variants of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F610456&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6ng6Gc%2F0HWng%2FxsEZ5%2FkOx&amp;TOPIC_ID=5813" target="_blank"><i>SAMD9</i></a> gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IMAGe syndrome</strong> – IMAGe syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614732&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4D1HyJBKzBbkUdRy51lLBD&amp;TOPIC_ID=5813" target="_blank">MIM #614732</a>) is characterized by <strong>i</strong>ntrauterine growth retardation, <strong>m</strong>etaphyseal dysplasia, <strong>a</strong>drenal hypoplasia congenita, and <strong>g</strong>enital anomalies. The defective gene (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600856&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrBCb5e3%2BHGRIZ%2F1MVCcUaO&amp;TOPIC_ID=5813" target="_blank"><i>CDKN1C</i></a>) in several unrelated pedigrees encodes cyclin-dependent kinase inhibitor 1C [<a href="#rid47">47,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Xp21 contiguous gene complex</strong> – The <em>NR0B1</em>/<em>DAX1</em> gene is contiguous with the dystrophin (Duchenne muscular dystrophy) and glycerol kinase (juvenile glycerol kinase deficiency) genes on the short arm of the X chromosome [<a href="#rid49">49</a>]. There are case reports of patients with deletions of this complex who present with adrenal insufficiency, muscular dystrophy, and intellectual disability. Other features include short stature, testicular abnormalities (eg, cryptorchidism and/or hypogonadism), and peculiar facies (drooping mouth and wide-set eyes) [<a href="#rid50">50,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RENI syndrome</strong> – RENI syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617575&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz4iEzchyxCqSdaXuvA0kGo5&amp;TOPIC_ID=5813" target="_blank">MIM #617575</a>; <strong>r</strong>enal, <strong>e</strong>ndocrine, <strong>n</strong>eurologic, and <strong>i</strong>mmune syndrome) is caused by pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603729&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyovrjNGyO5U9tLiT3558D1u&amp;TOPIC_ID=5813" target="_blank"><i>SGPL1</i></a> gene that result in accumulation of lysosomal sphingolipid species. The clinical phenotype includes early primary adrenal insufficiency, steroid-resistant nephrotic syndrome, cryptorchidism, primary hypothyroidism, and neurologic symptoms [<a href="#rid52">52,53</a>]. (See  <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">"Congenital nephrotic syndrome", section on 'Other genetic causes'</a>.)</p><p></p><p class="headingAnchor" id="H24"><span class="h1">INHERITED ADRENAL UNRESPONSIVENESS TO ADRENOCORTICOTROPIC HORMONE</span><span class="headingEndMark"> — </span>Familial glucocorticoid deficiency (FGD) and triple A syndrome are characterized by unresponsiveness of the adrenal gland to adrenocorticotropic hormone (ACTH). These are types of primary adrenal insufficiency because they are caused by genetic defects within the adrenal gland. However, mineralocorticoid secretion is typically normal so that their clinical presentation may be similar to disorders of central adrenal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/5815.html" rel="external">"Causes of central adrenal insufficiency in children"</a>.)</p><p class="headingAnchor" id="H623801627"><span class="h2">Familial glucocorticoid deficiency</span><span class="headingEndMark"> — </span>FGD type 1 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F202200&amp;token=87jLzclRwWxNoI%2BQq5Gg79odhHx1YN05LvlVAGqtHU4%2FbW2zhB93tJ5%2BNu4yBfED&amp;TOPIC_ID=5813" target="_blank">MIM #202200</a>) is caused by pathogenic variants of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607397&amp;token=87jLzclRwWxNoI%2BQq5Gg7522brIHwqZKuIwjrcaWuRe6jUGvt5iGY%2FJkruq%2BWDg7&amp;TOPIC_ID=5813" target="_blank"><i>MC2R</i></a> gene (also known as the ACTH receptor gene), which result in unresponsiveness to ACTH stimulation. The lack of ACTH stimulation of cells in the zona fasciculata and reticularis leads to decreased or no production of cortisol. In contrast, the zona glomerulosa is unaffected and continues to normally secrete aldosterone. FGD type 1 is an autosomal recessive disorder. In a series of pediatric patients with primary adrenal insufficiency that remained unexplained after excluding the most common causes, a detailed genetic analysis revealed <em>MC2R</em> pathogenic variants in 20 percent [<a href="#rid5">5</a>].</p><p>Other forms of FGD are caused by pathogenic variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609196&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaE%2FZsdyCnuOa5GkHrxyWKQQ&amp;TOPIC_ID=5813" target="_blank"><i>MRAP</i></a> gene (FGD type 2; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607398&amp;token=87jLzclRwWxNoI%2BQq5Gg78Y%2Bs3He49h%2B%2F2NdvuT%2BRwAdvQF5yRj2LTNges9TJHxO&amp;TOPIC_ID=5813" target="_blank">MIM #607398</a>), which encodes a membrane protein that interacts with MC2R [<a href="#rid54">54</a>]; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F607878&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrILrJj%2BLq4K1tQh0ZTUEyb&amp;TOPIC_ID=5813" target="_blank"><i>NNT</i></a> gene (FGD type 4; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F614736&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz6TVlINA7dqo2fbNj8vpWHU&amp;TOPIC_ID=5813" target="_blank">MIM #614736</a>), <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606448&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyr3XCHAZoYoyYqR28mxqvBK&amp;TOPIC_ID=5813" target="_blank"><i>TXNRD2</i></a> gene (FGD type 5; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F617825&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz7%2F2htc0ber6SpcJxRZXh19&amp;TOPIC_ID=5813" target="_blank">MIM #617825</a>), or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602638&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyo1D%2FZ8vgXVbIpJnP9HchX0&amp;TOPIC_ID=5813" target="_blank"><i>MCM4</i></a> gene [<a href="#rid5">5</a>].</p><p>Patients with FGD present early in childhood with feeding difficulties (eg, vomiting), failure to thrive, muscle weakness, hyperpigmentation, and hypoglycemia that may result in seizures. Laboratory evaluation reveals low fasting serum glucose and normal potassium, with or without dilutional hyponatremia. Cortisol secretion is low but not absent, causing subnormal but detectable plasma cortisol concentrations. Plasma ACTH levels are elevated. Aldosterone secretion is normal and also increases appropriately with sodium restriction.</p><p>A phenotype similar to FGD may be caused by variants in the <em>CYP11A1</em> gene. This was shown in a genetic analysis of an international cohort of 19 individuals with primary adrenal insufficiency of unknown etiology with pathogenic variants in <em>CYP11A1</em>. Many of these subjects were initially thought to have typical FGD based on their clinical features. These individuals were compound heterozygotes for pathogenic variants in <em>CYP11A1</em> that were predicted to be non-deleterious if present alone, based on modeling and in vitro studies [<a href="#rid55">55</a>]. Other pathogenic variants in <em>CYP11A1</em> cause a more severe phenotype. (See <a class="local">'Congenital adrenal hyperplasia'</a> above.)</p><p class="headingAnchor" id="H623801659"><span class="h2">Triple A syndrome</span><span class="headingEndMark"> — </span>The combination of ACTH-resistant cortisol deficiency, achalasia, and absent lacrimation is known as the triple A syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F231550&amp;token=87jLzclRwWxNoI%2BQq5Gg7391%2Bc7%2BZDyGQQdHnlSMpnKHLdwzDW2Jte5qsBMgsk%2BR&amp;TOPIC_ID=5813" target="_blank">MIM #231550</a>), also known as Allgrove syndrome. Many of these patients also have neurologic disorders including peripheral, autonomic, and central nervous system impairments [<a href="#rid56">56,57</a>]. This is an autosomal recessive disorder resulting from a defect in the <em>AAAS</em> gene, located on chromosome 12q13, that encodes the ALADIN protein (an acronym for alacrimia-achlasia-adrenal insufficiency and neurologic disorder). Some also have a mild defect in mineralocorticoid (aldosterone) secretion, particularly when salt restricted. In the above case series of patients with unexplained primary adrenal insufficiency, 7 percent had pathogenic variants in <em>AAAS</em> [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/2268.html" rel="external">"Achalasia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">DRUGS</span><span class="headingEndMark"> — </span>Drugs that inhibit cortisol synthesis include aminoglutethimide, high-dose <a class="drug drug_pediatric" data-topicid="13401" href="/z/d/drug information/13401.html" rel="external">ketoconazole</a>, <a class="drug drug_pediatric" data-topicid="12607" href="/z/d/drug information/12607.html" rel="external">metyrapone</a>, <a class="drug drug_pediatric" data-topicid="94785" href="/z/d/drug information/94785.html" rel="external">mitotane</a>, and <a class="drug drug_pediatric" data-topicid="12907" href="/z/d/drug information/12907.html" rel="external">etomidate</a>.</p><p class="headingAnchor" id="H23014111"><span class="h1">END-ORGAN UNRESPONSIVENESS</span><span class="headingEndMark"> — </span>In disorders due to end-organ unresponsiveness, clinical manifestations are similar to those seen in the primary deficiency of the specific hormone (eg, cortisol or aldosterone). Examples include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cortisol resistance</strong> – Familial or sporadic glucocorticoid resistance (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F615962&amp;token=87jLzclRwWxNoI%2BQq5Gg72db5zs3Sn9L7piPmfRMayxTEiyjQ9Lib5zMcGa57qSw&amp;TOPIC_ID=5813" target="_blank">MIM #615962</a>; also known as Chrousos syndrome) is a rare hereditary disorder resulting from pathogenic variants in the glucocorticoid receptor gene, leading to diminished cortisol action and secondary stimulation of adrenocorticotropic hormone (ACTH) release. Although there are high circulating levels of cortisol and ACTH, the patient is not Cushingoid. The glucocorticoid receptor defect results in clinical manifestations similar to those of glucocorticoid deficiency, combined with symptoms of mineralocorticoid and androgen excess.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aldosterone resistance</strong> – Pseudohypoaldosteronism type 1 is a rare hereditary disorder characterized by generalized resistance to the actions of aldosterone. The autosomal recessive form (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F264350&amp;token=87jLzclRwWxNoI%2BQq5Gg78Rbfi%2BUUxCuqAqNkndCx5rk933uoXRtWocuUdwXm167&amp;TOPIC_ID=5813" target="_blank">MIM #264350</a>) is lifelong and more severe (also associated with lower respiratory tract disease) and is due to loss-of-function pathogenic variants in the gene encoding the epithelial sodium channel. Patients with this form typically present in infancy with clinical manifestations similar to those of mineralocorticoid deficiency (salt wasting, with hypovolemia and hyperkalemia), except for increased levels of plasma and urinary aldosterone. The autosomal dominant form (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F177735&amp;token=87jLzclRwWxNoI%2BQq5Gg73QXJZAP9aaUKyMX9R6mG6C%2Fmu%2BXfABQtiElARfhjR5q&amp;TOPIC_ID=5813" target="_blank">MIM #177735</a>) is usually due to inactivating pathogenic variants in the mineralocorticoid receptor gene. These disorders are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2371.html" rel="external">"Genetic disorders of the collecting tubule sodium channel: Liddle syndrome and pseudohypoaldosteronism type 1", section on 'Pseudohypoaldosteronism type 1'</a>.)</p><p></p><p class="headingAnchor" id="H3012477241"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112295.html" rel="external">"Society guideline links: Adrenal insufficiency"</a>.)</p><p class="headingAnchor" id="H104887169"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16935.html" rel="external">"Patient education: Congenital adrenal hyperplasia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Primary adrenal insufficiency is defined as the impaired synthesis and/or release of adrenocortical hormones on account of disease intrinsic to the adrenal cortex. Central adrenal insufficiency is characterized by lack of adrenocorticotropic hormone (ACTH) stimulation of cortisol production. (See <a class="local">'Pathogenetic categories of primary adrenal insufficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The clinical manifestations of adrenal insufficiency depend on the type of hormonal class affected and severity of the defect(s)  (<a class="graphic graphic_table graphicRef66355" href="/z/d/graphic/66355.html" rel="external">table 1</a>). The adrenal hormones are glucocorticoids (eg, cortisol), mineralocorticoids (eg, aldosterone), and androgens (eg, dehydroepiandrosterone [DHEA]). Adrenal crisis results from acute adrenal insufficiency, which requires prompt recognition and treatment, as summarized in the accompanying table  (<a class="graphic graphic_table graphicRef61357" href="/z/d/graphic/61357.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Primary adrenal insufficiency is caused by either genetic defects or acquired disease that affect adrenal function by the following processes  (<a class="graphic graphic_table graphicRef81494" href="/z/d/graphic/81494.html" rel="external">table 3</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Steroidogenic disorders</strong> – Including congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, which is the most common cause of primary adrenal insufficiency in children. (See <a class="local">'Disorders of steroidogenesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adrenal damage</strong> – Including autoimmune injury (Addison disease) and critical illness-related corticosteroid insufficiency (CIRCI). (See <a class="local">'Adrenal damage or dysfunction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Peroxisomal disorders</strong> – Including adrenoleukodystrophy (ALD), which is seen in boys. It can present with neurologic dysfunction, adrenal insufficiency, or both  (<a class="graphic graphic_table graphicRef70311" href="/z/d/graphic/70311.html" rel="external">table 5</a>). (See <a class="local">'Peroxisomal disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetic causes of adrenal hypoplasia</strong> – Including adrenal hypoplasia congenita, which typically presents in neonates with signs and symptoms of a salt-losing crisis similar to that seen in classic CAH. In addition, several syndromes are associated with adrenal hypoplasia (MIRAGE syndrome, IMAGe syndrome, and a form of steroid-resistant nephrotic syndrome). (See <a class="local">'Genetic causes of adrenal hypoplasia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inherited adrenal unresponsiveness to ACTH</strong> – Including familial glucocorticoid deficiency (FGD) and triple A syndrome. (See <a class="local">'Inherited adrenal unresponsiveness to adrenocorticotropic hormone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Drugs</strong> – Including <a class="drug drug_pediatric" data-topicid="13401" href="/z/d/drug information/13401.html" rel="external">ketoconazole</a>. (See <a class="local">'Drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – A clinical approach to the diagnosis of adrenal insufficiency and determining its cause is presented separately. (See  <a class="medical medical_review" href="/z/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children"</a>.)</p><p></p><p class="headingAnchor" id="H3154703750"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Patricia A Donohoue, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:364.</a></li><li><a class="nounderline abstract_t">Perry R, Kecha O, Paquette J, et al. Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. J Clin Endocrinol Metab 2005; 90:3243.</a></li><li><a class="nounderline abstract_t">Wijaya M, Huamei M, Jun Z, et al. Etiology of primary adrenal insufficiency in children: a 29-year single-center experience. J Pediatr Endocrinol Metab 2019; 32:615.</a></li><li><a class="nounderline abstract_t">Capalbo D, Moracas C, Cappa M, et al. Primary Adrenal Insufficiency in Childhood: Data From a Large Nationwide Cohort. J Clin Endocrinol Metab 2021; 106:762.</a></li><li><a class="nounderline abstract_t">Buonocore F, Maharaj A, Qamar Y, et al. Genetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years' Experience in the UK. J Endocr Soc 2021; 5:bvab086.</a></li><li><a class="nounderline abstract_t">Guran T, Buonocore F, Saka N, et al. Rare Causes of Primary Adrenal Insufficiency: Genetic and Clinical Characterization of a Large Nationwide Cohort. J Clin Endocrinol Metab 2016; 101:284.</a></li><li><a class="nounderline abstract_t">Huang N, Pandey AV, Agrawal V, et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005; 76:729.</a></li><li><a class="nounderline abstract_t">Hui E, Yeung MC, Cheung PT, et al. The clinical significance of aldosterone synthase deficiency: report of a novel mutation in the CYP11B2 gene. BMC Endocr Disord 2014; 14:29.</a></li><li><a class="nounderline abstract_t">Anderson RA, Byrum RS, Coates PM, Sando GN. Mutations at the lysosomal acid cholesteryl ester hydrolase gene locus in Wolman disease. Proc Natl Acad Sci U S A 1994; 91:2718.</a></li><li><a class="nounderline abstract_t">Patrick AD, Lake BD. Deficiency of an acid lipase in Wolman's disease. Nature 1969; 222:1067.</a></li><li class="breakAll">Hoffman EP, Barr ML, Giovanni MA, Murray MF.. GeneReviews®, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A. (Eds), University of Washington, Seattle, Seattle (WA) 1993.</li><li><a class="nounderline abstract_t">Kyosen SO, Geocze S, Yamamoto MH, Martins AM. Endoscopic Findings in Lysosomal Acid Lipase Deficiency. J Pediatr Gastroenterol Nutr 2019; 68:e105.</a></li><li><a class="nounderline abstract_t">Pericleous M, Kelly C, Wang T, et al. Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency. Lancet Gastroenterol Hepatol 2017; 2:670.</a></li><li><a class="nounderline abstract_t">Zhang B, Porto AF. Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr 2013; 56:682.</a></li><li><a class="nounderline abstract_t">Burton BK, Deegan PB, Enns GM, et al. Clinical Features of Lysosomal Acid Lipase Deficiency. J Pediatr Gastroenterol Nutr 2015; 61:619.</a></li><li><a class="nounderline abstract_t">Hamilton J, Jones I, Srivastava R, Galloway P. A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta 2012; 413:1207.</a></li><li><a class="nounderline abstract_t">Jones SA, Rojas-Caro S, Quinn AG, et al. Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. Orphanet J Rare Dis 2017; 12:25.</a></li><li><a class="nounderline abstract_t">Burton BK, Balwani M, Feillet F, et al. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med 2015; 373:1010.</a></li><li><a class="nounderline abstract_t">Malinová V, Balwani M, Sharma R, et al. Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study. Liver Int 2020; 40:2203.</a></li><li><a class="nounderline abstract_t">Vijay S, Brassier A, Ghosh A, et al. Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies. Orphanet J Rare Dis 2021; 16:13.</a></li><li><a class="nounderline abstract_t">Burton BK, Sanchez AC, Kostyleva M, et al. Long-Term Sebelipase Alfa Treatment in Children and Adults With Lysosomal Acid Lipase Deficiency. J Pediatr Gastroenterol Nutr 2022; 74:757.</a></li><li class="breakAll">Manufacturer's prescribing information for KANUMA (sebelipase alfa), 12/2015. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125561s000lbl.pdf (Accessed on August 22, 2021).</li><li><a class="nounderline abstract_t">Krivit W, Peters C, Dusenbery K, et al. Wolman disease successfully treated by bone marrow transplantation. Bone Marrow Transplant 2000; 26:567.</a></li><li><a class="nounderline abstract_t">Stein J, Garty BZ, Dror Y, et al. Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation. Eur J Pediatr 2007; 166:663.</a></li><li><a class="nounderline abstract_t">Fitzky BU, Witsch-Baumgartner M, Erdel M, et al. Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. Proc Natl Acad Sci U S A 1998; 95:8181.</a></li><li><a class="nounderline abstract_t">Andersson HC, Frentz J, Martínez JE, et al. Adrenal insufficiency in Smith-Lemli-Opitz syndrome. Am J Med Genet 1999; 82:382.</a></li><li><a class="nounderline abstract_t">Khuri FJ, Alton DJ, Hardy BE, et al. Adrenal hemorrhage in neonates: report of 5 cases and review of the literature. J Urol 1980; 124:684.</a></li><li><a class="nounderline abstract_t">Peterson P, Pitkänen J, Sillanpää N, Krohn K. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity. Clin Exp Immunol 2004; 135:348.</a></li><li><a class="nounderline abstract_t">Sanaker PS, Husebye ES, Fondenes O, Bindoff LA. Clinical evolution of Kearns-Sayre syndrome with polyendocrinopathy and respiratory failure. Acta Neurol Scand Suppl 2007; 187:64.</a></li><li><a class="nounderline abstract_t">Artuch R, Pavía C, Playán A, et al. Multiple endocrine involvement in two pediatric patients with Kearns-Sayre syndrome. Horm Res 1998; 50:99.</a></li><li><a class="nounderline abstract_t">Calderwood L, Holm IA, Teot LA, Anselm I. Adrenal Insufficiency in Mitochondrial Disease: A Rare Case of GFER-Related Mitochondrial Encephalomyopathy and Review of the Literature. J Child Neurol 2016; 31:190.</a></li><li><a class="nounderline abstract_t">Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med 2017; 43:1751.</a></li><li><a class="nounderline abstract_t">Aneja R, Carcillo JA. What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock? Arch Dis Child 2007; 92:165.</a></li><li><a class="nounderline abstract_t">Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock. Crit Care Med 2017; 45:1061.</a></li><li><a class="nounderline abstract_t">Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629.</a></li><li><a class="nounderline abstract_t">Ng PC, Lee CH, Lam CW, et al. Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2004; 89:F119.</a></li><li><a class="nounderline abstract_t">Masumoto K, Kusuda S, Aoyagi H, et al. Comparison of serum cortisol concentrations in preterm infants with or without late-onset circulatory collapse due to adrenal insufficiency of prematurity. Pediatr Res 2008; 63:686.</a></li><li><a class="nounderline abstract_t">Huffnagel IC, Laheji FK, Aziz-Bose R, et al. The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration. J Clin Endocrinol Metab 2019; 104:118.</a></li><li><a class="nounderline abstract_t">Zhu J, Eichler F, Biffi A, et al. The Changing Face of Adrenoleukodystrophy. Endocr Rev 2020; 41.</a></li><li><a class="nounderline abstract_t">Regelmann MO, Kamboj MK, Miller BS, et al. Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn Screen. J Clin Endocrinol Metab 2018; 103:4324.</a></li><li><a class="nounderline abstract_t">Dubey P, Raymond GV, Moser AB, et al. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr 2005; 146:528.</a></li><li><a class="nounderline abstract_t">Moser HW, Moser AB, Smith KD, et al. Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis 1992; 15:645.</a></li><li><a class="nounderline abstract_t">Klouwer FC, Berendse K, Ferdinandusse S, et al. Zellweger spectrum disorders: clinical overview and management approach. Orphanet J Rare Dis 2015; 10:151.</a></li><li class="breakAll">Steinberg SJ, Raymond GV, Braverman NE, Moser AB.. GeneReviews®, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A. (Eds), University of Washington, Seattle, Seattle (WA) 1993.</li><li><a class="nounderline abstract_t">Suntharalingham JP, Buonocore F, Duncan AJ, Achermann JC. DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease. Best Pract Res Clin Endocrinol Metab 2015; 29:607.</a></li><li><a class="nounderline abstract_t">Lin L, Philibert P, Ferraz-de-Souza B, et al. Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function. J Clin Endocrinol Metab 2007; 92:991.</a></li><li><a class="nounderline abstract_t">Vilain E, Le Merrer M, Lecointre C, et al. IMAGe, a new clinical association of intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies. J Clin Endocrinol Metab 1999; 84:4335.</a></li><li><a class="nounderline abstract_t">Arboleda VA, Lee H, Parnaik R, et al. Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome. Nat Genet 2012; 44:788.</a></li><li><a class="nounderline abstract_t">Patil S, Bartley JA, Murray JC, et al. X-linked glyceral kinase, adrenal hypoplasia, and myopathy maps to Xq21. Cytogenet 1985; 40:720.</a></li><li><a class="nounderline abstract_t">Bartley JA, Patil S, Davenport S, et al. Duchenne muscular dystrophy, glycerol kinase deficiency, and adrenal insufficiency associated with Xp21 interstitial deletion. J Pediatr 1986; 108:189.</a></li><li><a class="nounderline abstract_t">Wise JE, Matalon R, Morgan AM, McCabe ER. Phenotypic features of patients with congenital adrenal hypoplasia and glycerol kinase deficiency. Am J Dis Child 1987; 141:744.</a></li><li><a class="nounderline abstract_t">Prasad R, Hadjidemetriou I, Maharaj A, et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. J Clin Invest 2017; 127:942.</a></li><li><a class="nounderline abstract_t">Settas N, Persky R, Faucz FR, et al. SGPL1 Deficiency: A Rare Cause of Primary Adrenal Insufficiency. J Clin Endocrinol Metab 2019; 104:1484.</a></li><li><a class="nounderline abstract_t">Metherell LA, Chapple JP, Cooray S, et al. Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2. Nat Genet 2005; 37:166.</a></li><li><a class="nounderline abstract_t">Maharaj A, Buonocore F, Meimaridou E, et al. Predicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing. J Endocr Soc 2019; 3:201.</a></li><li><a class="nounderline abstract_t">Prpic I, Huebner A, Persic M, et al. Triple A syndrome: genotype-phenotype assessment. Clin Genet 2003; 63:415.</a></li><li><a class="nounderline abstract_t">Singh K, Puri RD, Bhai P, et al. Clinical heterogeneity and molecular profile of triple A syndrome: a study of seven cases. J Pediatr Endocrinol Metab 2018; 31:799.</a></li></ol></div><div id="topicVersionRevision">Topic 5813 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26760044" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15811934" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31141483" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Etiology of primary adrenal insufficiency in children: a 29-year single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33247909" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Primary Adrenal Insufficiency in Childhood: Data From a Large Nationwide Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34258490" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Genetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years' Experience in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26523528" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Rare Causes of Primary Adrenal Insufficiency: Genetic and Clinical Characterization of a Large Nationwide Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793702" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24694176" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The clinical significance of aldosterone synthase deficiency: report of a novel mutation in the CYP11B2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8146180" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mutations at the lysosomal acid cholesteryl ester hydrolase gene locus in Wolman disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5787090" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Deficiency of an acid lipase in Wolman's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5787090" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Deficiency of an acid lipase in Wolman's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29762191" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Endoscopic Findings in Lysosomal Acid Lipase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28786388" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23403440" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26252914" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical Features of Lysosomal Acid Lipase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22483793" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A new method for the measurement of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28179030" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26352813" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32657505" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33407676" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35442238" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-Term Sebelipase Alfa Treatment in Children and Adults With Lysosomal Acid Lipase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35442238" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-Term Sebelipase Alfa Treatment in Children and Adults With Lysosomal Acid Lipase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11019848" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Wolman disease successfully treated by bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17033804" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Successful treatment of Wolman disease by unrelated umbilical cord blood transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9653161" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10069708" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Adrenal insufficiency in Smith-Lemli-Opitz syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7005460" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adrenal hemorrhage in neonates: report of 5 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15008965" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17419832" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical evolution of Kearns-Sayre syndrome with polyendocrinopathy and respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9701704" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Multiple endocrine involvement in two pediatric patients with Kearns-Sayre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26018198" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Adrenal Insufficiency in Mitochondrial Disease: A Rare Case of GFER-Related Mitochondrial Encephalomyopathy and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940011" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003064" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28509730" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : American College of Critical Care Medicine Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15084695" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Measurements of serum free cortisol in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14977894" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520332" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of serum cortisol concentrations in preterm infants with or without late-onset circulatory collapse due to adrenal insufficiency of prematurity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30252065" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32364223" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Changing Face of Adrenoleukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30289543" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn Screen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15812458" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1528023" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adrenoleukodystrophy: phenotypic variability and implications for therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26627182" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Zellweger spectrum disorders: clinical overview and management approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26627182" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Zellweger spectrum disorders: clinical overview and management approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26303087" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : DAX-1 (NR0B1) and steroidogenic factor-1 (SF-1, NR5A1) in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17200175" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal adrenal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10599684" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : IMAGe, a new clinical association of intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22634751" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : X-linked glyceral kinase, adrenal hypoplasia, and myopathy maps to Xq21</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3003318" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Duchenne muscular dystrophy, glycerol kinase deficiency, and adrenal insufficiency associated with Xp21 interstitial deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3035918" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Phenotypic features of patients with congenital adrenal hypoplasia and glycerol kinase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28165343" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30517686" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : SGPL1 Deficiency: A Rare Cause of Primary Adrenal Insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654338" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30620006" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Predicted Benign and Synonymous Variants in CYP11A1 Cause Primary Adrenal Insufficiency Through Missplicing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12752575" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Triple A syndrome: genotype-phenotype assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29874194" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical heterogeneity and molecular profile of triple A syndrome: a study of seven cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
